26 active not recruiting, 24 recruiting, 19 completed, 14 terminated. 94 Phase 2, 21 Phase 1, 3 Phase 3.
Follow CT-P10: new trials by email Literature Review of CT-P10 trials Research Report on CT-P10
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 58 | 2026-12-21 | 2026-10-22 |
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-10-23 | 2026-10-29 |
| Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma Rituximab, Tafasitamab, Biospecimen Collection - Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma | Phase 2 | Recruiting | University of Washington | 30 | 2026-10-09 | 2026-10-15 |
| Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Adult Burkitt Lymphoma | Phase 2 | Not yet recruiting | AIDS Malignancy Consortium | 43 | 2026-09-17 | 2026-10-16 |
| Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Biopsy Procedure, Biospecimen Collection - Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | City of Hope Medical Center | 43 | 2026-07-27 | 2026-08-28 |
| Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 84 | 2026-05-29 | 2026-07-31 |
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia | Phase 2 | Suspended | University of Washington | 30 | 2026-05-08 | 2026-09-29 |
| Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma Cyclophosphamide, Doxorubicin, Etoposide - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 2 | Recruiting | University of Washington | 33 | 2026-03-30 | 2026-08-13 |
| Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma | Phase 2 | Recruiting | University of Washington | 18 | 2025-12-07 | 2026-10-21 |
| Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 53 | 2025-10-10 | 2026-10-13 |
| Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cytarabine - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | University of California, Davis | 25 | 2025-07-31 | 2026-06-30 |
| Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 30 | 2025-06-02 | 2026-10-30 |
| Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 2 | Recruiting | Mayo Clinic | 41 | 2025-04-02 | 2026-10-20 |
| Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Nemtabrutinib - Mantle Cell Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 27 | 2025-01-22 | 2026-03-13 |
| Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia | Phase 2 | Withdrawn | Northwestern University | 2024-03-29 | 2024-02-29 | |
| Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Nodular Lymphocyte Predominant B-Cell Lymphoma, Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 70 | 2024-01-23 | 2026-10-14 |
| Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma Cyclophosphamide, Doxorubicin, Etoposide - Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | Phase 2 | Active not recruiting | University of California, Davis | 24 | 2023-05-24 | 2026-09-28 |
| Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia Cyclophosphamide, Doxorubicin, Etoposide - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Phase 2 | Active not recruiting | University of Washington | 32 | 2023-03-27 | 2026-05-11 |
| Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder Biopsy, Biospecimen Collection, Computed Tomography - Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder | Phase 2 | Recruiting | Timothy Voorhees | 28 | 2023-03-23 | 2026-04-14 |
Showing 20 of 94. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (20) · Lymphoma, Mantle-Cell (20) · Burkitt Lymphoma (18) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (13) · Lymphoma, Follicular (12) · Leukemia, Lymphocytic, Chronic, B-Cell (9) · Lymphoma, B-Cell (9) · Lymphoma, B-Cell, Marginal Zone (9) · Lymphoma, Non-Hodgkin (7) · Hodgkin Disease (4) · Leukemia, Myeloid, Accelerated Phase (4) · Leukemia, Myelomonocytic, Chronic (4) · Lymphoma (4) · Waldenstrom Macroglobulinemia (4) · Blast Crisis (3)
M.D. Anderson Cancer Center (44) · National Cancer Institute (NCI) (12) · University of Washington (10) · City of Hope Medical Center (7) · Academic and Community Cancer Research United (3) · Fred Hutchinson Cancer Center (2) · Mayo Clinic (2) · Northwestern University (2) · University of California, Davis (2) · AIDS Malignancy Consortium (1) · Barbara Ann Karmanos Cancer Institute (1) · Children's Oncology Group (1) · David Bond, MD (1) · ECOG-ACRIN Cancer Research Group (1) · OHSU Knight Cancer Institute (1)
United States (91) · Canada (2)
Elias Jabbour (7) · Farhad Ravandi-Kashani (2) · Geoffrey Shouse (2) · Grzegorz S Nowakowski (2) · Issa F Khouri (2) · Issa Khouri (2) · Jan A Burger (2) · Joseph M Tuscano (2) · Mengyang Di, MD, PhD (2) · Ranjit Nair (2) · Ryan D. Cassaday (2) · Yago L Nieto (2) · Ajay Gopal (1) · Ajay K. Gopal (1)
PMID 39319495, PMID 34515338, PMID 34797699, PMID 35952327, PMID 41671463, PMID 21821712, PMID 23834234, PMID 25439689, PMID 26250576, PMID 26432046, PMID 26640039, PMID 27118452, PMID 28945884, PMID 29531316, PMID 29785709, PMID 30501869, PMID 30530801, PMID 30575311, PMID 32430507, PMID 33191168, PMID 34634256, PMID 34686472, PMID 35015819, PMID 35074072, PMID 35622074, PMID 35787017, PMID 36279879, PMID 36385536, PMID 36600670, PMID 36841758, PMID 37183115, PMID 37985359, PMID 38163318, PMID 38207208, PMID 39352751, PMID 40706069, PMID 41845899, PMID 42305039, PMID 42660130
P30CA016672 (7), P30CA033572 (7), U10CA180821 (4), P30CA015083 (3), P30CA015704 (3), U10CA180820 (3), U10CA180888 (3), P30CA060553 (2), P30CA093373 (2), U10CA021115 (2), U10CA031946 (2), UM1CA121947 (2), P01CA044991 (1), P30CA012197 (1), P30CA022453 (1)